NCT00035061

Brief Summary

Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

20 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2002

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 3, 2002

Completed
Last Updated

July 19, 2006

Status Verified

July 1, 2006

First QC Date

May 2, 2002

Last Update Submit

July 18, 2006

Conditions

Keywords

Bladder CancerMetastaticRecurrentTransitional cell carcinoma of the urothelium

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
  • You must have at least one tumor that can be physically measured or scanned by x-ray.
  • You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

You may not qualify if:

  • You may not have used an experimental medicine or device within the past month.
  • Cancer that has spread to your brain.
  • If you are unwilling or unable to take folic acid or vitamin B12 supplements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (20)

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Palo Alto, California, United States

Location

Unknown Facility

Boca Raton, Florida, United States

Location

Unknown Facility

Tampa, Florida, United States

Location

Unknown Facility

Decatur, Illinois, United States

Location

Unknown Facility

Indianapolis, Indiana, United States

Location

Unknown Facility

Lafayette, Indiana, United States

Location

Unknown Facility

Muncie, Indiana, United States

Location

Unknown Facility

South Bend, Indiana, United States

Location

Unknown Facility

Lenexa, Kansas, United States

Location

Unknown Facility

Saint Mathews, Kentucky, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

Omaha, Nebraska, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, United States

Location

Unknown Facility

Nashville, Tennessee, United States

Location

Unknown Facility

Fort Worth, Texas, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

Seattle, Washington, United States

Location

MeSH Terms

Conditions

Urologic NeoplasmsNeoplasm MetastasisUrinary Bladder NeoplasmsRecurrence

Interventions

Pemetrexed

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrologic DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsUrinary Bladder DiseasesDisease Attributes

Intervention Hierarchy (Ancestors)

GuanineHypoxanthinesPurinonesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsGlutamatesAmino Acids, AcidicAmino AcidsAmino Acids, Peptides, and ProteinsAmino Acids, Dicarboxylic

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 2, 2002

First Posted

May 3, 2002

Last Updated

July 19, 2006

Record last verified: 2006-07

Locations